|
Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL). |
|
|
|
Consulting or Advisory Role - Merck |
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst) |
Expert Testimony - Medscape/Bayer; Nanobiotix |
Travel, Accommodations, Expenses - Sanofi/Regeneron |
|
|
Research Funding - Celgene |
|
Juan Manuel Manuel Sepulveda Sanchez |
Honoraria - AbbVie; Astellas Pharma; Bayer; Celgene; Pfizer; Roche |
Consulting or Advisory Role - Abbvie; Celgene; Pfizer |
Speakers' Bureau - Astellas Pharma |
Research Funding - Catalysis; Pfizer |
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma; Celgene; Ipsen |
|
|
No Relationships to Disclose |
|
Tatiana Hernandez-Guerrero |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
|
|
|
|
Patents, Royalties, Other Intellectual Property - Celgene |
|
|
|
|
|
Stock and Other Ownership Interests - Celgene; Pfizer |
|
|
|
Stock and Other Ownership Interests - Celgene |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
|
|
Travel, Accommodations, Expenses - Celgene |